Skip to main content
OpenTrials
Completed

NCT Number: NCT04488900

Evaluation of the Safety and Tolerability of CKD-508 in Healthy Subjects

This study is a first-in-human, randomized, placebo-controlled, 4-part, single ascending dose and multiple ascending dose study. The study is designed to assess the safety, tolerability, PK, and PD and food effect of orally administered CKD-508 capsules and tablets in healthy subjects.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Northwick Park Hospital

Harrow, Middlesex, HA1 3UJ, United Kingdom

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject voluntarily agrees to participate in this study and signs an Independent Ethics Committee (IEC)-approved informed consent prior to performing any of the Screening Visit procedures.
  • Males and females between 18 to 55 years of age, inclusive, at the Screening Visit.
  • Females of non-childbearing potential (surgically sterile [hysterectomy or oophorectomy] or postmenopausal (amenorrhea for more than 12 months with follicle-stimulating hormone (FSH) in postmenopausal range confirmed by an FSH test).
  • Males must be unable to procreate (defined as surgically sterile [i.e., had a vasectomy ≥6 months prior to screening]) or must agree to use highly effective form of birth control from screening through 90 days after study completion.
  • Non-smokers (or other nicotine use) as determined by history (no nicotine use over the past 6 months).

Exclusion criteria

  • Subject has clinically significant history or evidence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, neurological, immunological or psychiatric disorder(s) as determined by the PI or designee.
  • Subject has any disorder that would interfere with the absorption, distribution, metabolism or excretion of drugs.
  • Subject has any concurrent disease or condition that, in the opinion of the PI, would make the subject unsuitable for participation in the clinical study.
  • Subject has history of alcohol and/or illicit drug abuse within 2 years of Screening Visit.
  • Subject has positive test for Hepatitis B surface antigen (HBsAg), Hepatitis C antibody or human immunodeficiency virus (HIV) antibody.

Treatment and study plan

CKD-508 Capsule

Drug

Investigational drug

Placebo capsule

Drug

Placebo

CKD-508 Tablet

Drug

Investigational drug

Placebo Tablet

Drug

Placebo

Primary outcomes

  1. Safety and tolerability including treatment-emergent AE and treatment-emergent SAE

    Time frame: 28 days post the final dose

Secondary outcomes

  1. Maximum plasma CKD-508 concentrations after dosing

    Time frame: 28 days post the final dose

    Peak plasma concentration (Cmax)

  2. Time of maximum plasma CKD-508 concentrations after dosing

    Time frame: 28 days post the final dose

    Time of peak plasma concentration (Tmax)

  3. Changes from baseline in plasma CKD-508 concentrations in time after dosing

    Time frame: 28 days post the final dose

    Area under the plasma concentration versus time curve (AUC)

  4. Changes from baseline in CETP activity after dosing

    Time frame: 28 days post the final dose

    Pharmacodynamics endpoint

  5. Changes from baseline in lipid parameters after dosing

    Time frame: 14 days post the final dose

    including, but not limited to the following: LDL-C, etc.

    Pharmacodynamics endpoint

Sponsors and collaborators

Lead sponsor

Chong Kun Dang Pharmaceutical

Industry

Registry information

Official study title

A Phase 1, First-in-Human, Double-blind, Randomized, Placebo Controlled Study to Assess the Safety, Tolerability, PK and PD and Food Effect of CKD-508 After Single and Multiple Ascending Oral Dose Administration in Healthy Adult Subjects

Important dates

Study start
2020
Primary completion
2023
Study completion
2023
First posted
Jul 28, 2020
Registry last updated
Feb 15, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.